A Phase 3 interventional study of Trastuzumab Deruxtecan in Breast Cancer, sponsored by AstraZeneca. Active, not recruiting at 81 sites in 18 countries. Open to participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2026-11-12.
Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 58 studies testing trastuzumab deruxtecan in Breast Neoplasms — 31 open to participants now, 45 under way, 8 of them phase 3. trastuzumab deruxtecan · Breast Neoplasms.
Among the 58 studies testing trastuzumab deruxtecan in Breast Neoplasms, this one is the 8th largest by enrollment, is one of 3 that started in 2021, is one of 12 in phase 3, reaches primary completion later than 1 of the 44 other live ones, and was the 18th registered.
14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.
Browse Breast Neoplasms studies →31 of the 58 studies testing trastuzumab deruxtecan in Breast Neoplasms are open now, in 12 countries. Recruiting first, the newest first:
Daiichi Sankyo · Sites in United States
Ages 18+
Memorial Sloan Kettering Cancer Center · Sites in United States
Ages 18+
SOLTI Breast Cancer Research Group · Sites in France, Germany, Spain
Ages 18+
Kristina A. Fanucci · Sites in United States
Ages 18+
Institut Claudius Regaud · Sites in France
Ages 18+
By country, each count listing its studies:
trastuzumab deruxtecan: first FDA approval 2019 (ENHERTU), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →
Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.
This study: 18 Years to 130 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, trastuzumab deruxtecan is the treatment under test here. Read study by study →
58 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 37 · Phase 3 12 · Phase 4 2
First in 2017; this study’s year is marked. 3 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 506 is above the median of 72 across 10,908 interventional studies indexed under Breast Neoplasms.
Median enrollment 139 across the 58 interventional studies. Of the 12 that completed or were terminated, 10 (83%) have results posted.
This tab as a report to print or save as PDF → With an account.
21 of 58 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
198 studies in Breast Neoplasms by AstraZeneca: 20 open now, 50 under way, 24 of them phase 3. Of 144 finished, 32 (22%) have results posted.
Among the 198 studies in Breast Neoplasms by AstraZeneca, this one is the 29th largest by enrollment of the 125 interventional ones that give a count, is one of 13 that started in 2021, is one of 46 in phase 3, reaches primary completion later than 5 of the 49 other live ones, and was the 140th registered.
AstraZeneca’s Breast Neoplasms studies by the year they started, since 1996.
13 of the studies testing trastuzumab deruxtecan in Breast Neoplasms that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04784715Phase 3AstraZenecaTrastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09) | 2027-05-03 |
| NCT05950945Phase 3Daiichi SankyoTrastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer | 2027-10-01 |
| NCT06048718MedSIRT-DXd Therapy for HER2-low Breast Cancer Patients With Brain Metastases | 2026-11 |
| NCT04553770Jonsson Comprehensive Cancer CenterTrastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer | 2026-12-31 |
| NCT06486883MedSIRSafety and Efficacy of T-DXd vs. CDK4/6i-based ET as First-line Therapy of HR-positive and HER2-low/Ultralow Advanced Breast Cancer Patients Classified as Non-luminal Subtype | 2027-01 |
Add all 13 to your calendar (.ics) → With an account.
Among the 58 studies testing trastuzumab deruxtecan in Breast Neoplasms, from their registry updates:
Among AstraZeneca’s 198 in Breast Neoplasms:
This tab as a report to print or save as PDF → With an account.
This is open-label, multicenter, international study, assessing the efficacy and safety of Trastuzumab deruxtecan (T-DXd) in participants with or without brain metastasis (BMs), with previously-treated advanced/metastatic HER2-positive breast cancer whose disease has progressed on prior anti-HER2-based regimens and who received no more than 2 lines/regimens of therapy in the metastatic setting (excluding tucatinib).
Approximately 500 eligible participants will be enrolled into 1 of 2 cohorts (250 participants in each cohort) according to the presence or absence of BMs at baseline. Cohort 1 will include participants without BM at baseline and Cohort 2 will consist of participants with BM at baseline.
After study intervention discontinuation, all participants will undergo an end-of-treatment visit (within 7 days of discontinuation) and will be followed up for safety assessments 40 (+ up to 7) days after the discontinuation of all study intervention.
All participants will be followed up for survival status and duration of treatment on subsequent therapies after intervention discontinuation every 3 months (± 14 days) from the date of the safety follow-up until death, withdrawal of consent, or the end of the study, as per defined in the protocol.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with or without BM at baseline will receive intravenous (IV) T-DXd, 5.4 mg/kg, every 3 weeks (21-day cycle) until Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1) defined radiological progression outside central nervous system, unacceptable toxicity, withdrawal of consent, or another criterion for discontinuation is met.
Drug: Trastuzumab Deruxtecan
Participants will receive T-DXd administered using an IV bag containing 5% (w/v) dextrose injection infusion solution.
Also known as: fam-trastuzumab deruxtecan-nxki
Objective Response Rate (ORR) in Cohort 1 (Participants Without Brain Metastasis at Baseline)
The ORR is defined as the percentage (%) of participants who have a confirmed complete response (CR) or confirmed partial response (PR), as determined by independent central review (ICR) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.
Time frame: From first dose (Day 1) to progression of disease (up to 2 years 7 months)
Progression-free Survival (PFS) Rate at 12 Months in Cohort 2 (Participants With Brain Metastasis at Baseline)
The PFS rate is the percentage of participants alive and free of disease progression at 12 months, estimated by the Kaplan-Meier method.
Time frame: At 12 months
Survival Rate at 12 Months
Survival rate is the percentage of participants alive at 12 months, estimated by the Kaplan-Meier method.
Time frame: At 12 Months
Objective Response Rate in Cohort 2 (Participants With Brain Metastasis at Baseline)
The ORR is defined as the percentage of participants who have a confirmed CR or confirmed PR, as determined by ICR per RECIST 1.1.
Time frame: From first dose (Day 1) to progression of disease (up to 2 years 7 months)
Duration of Response (DoR)
Duration of response is defined as the time from the date of first documented confirmed response until date of documented progression per RECIST 1.1 as assessed by ICR or death due to any cause.
Time frame: From the date of first documented confirmed response until date of documented progression (up to 2 years 7 months)
Time to Progression
Time to progression by RECIST 1.1 per ICR is defined as the time from the date of the first dose of study intervention to the date of documented disease progression.
Time frame: From first dose (Day 1) to progression of disease (up to 2 years 7 months)
Duration of Treatment on Subsequent Lines of Therapy
Duration of treatment on subsequent therapy is defined as the time from the date of first dose of a subsequent therapy until date of the last dose of that therapy.
Time frame: From the date of first dose of a subsequent therapy until date of last dose of therapy (up to 2 years 7 months)
Second Progression-Free Survival Rate at 12 Months
Second progression-free survival rate is the percentage of participants alive and free from a second progression on next-line treatment at 12 months, estimated by the Kaplan-Meier method. The second progression is defined as the earliest progression event subsequent to the first anti-cancer therapy after the initial progression.
Time frame: At 12 Months
Incidence of New Symptomatic Central Nervous System (CNS) Metastasis During Treatment Without CNS Metastasis at Baseline (Cohort 1)
The incidence rate is defined as proportion of participants with new symptomatic CNS metastases during treatment period in participants without symptomatic CNS metastasis at baseline.
Time frame: From first dose (Day 1) to end of treatment (up to 2 years 7 months)
Time to Next Progression (CNS or Extracranial) or Death
The time to next progression is defined as the time from the date of the first documented isolated CNS progression to the date of the next documented disease progression (CNS or extracranial) per RECIST 1.1 or death and has been summarized descriptively in participants who have developed isolated CNS progression, receive local therapy, and continue on protocol therapy.
Time frame: From date of first documented isolated CNS progression to the date of the next documented disease progression (up to 2 years 7 months)
Site (CNS vs Extracranial vs Both) of Next Progression
Site of next progression (CNS \[CNS RECIST 1.1\] or extracranial \[systemic RECIST 1.1\] in participants who developed isolated CNS progression, received local therapy, and continued on protocol therapy.
Time frame: From the date of the first documented isolated CNS progression to the date of the next documented CNS disease progression (up to 2 years 7 months)
Central Nervous System Progression-free Survival Rate at 12 Months in Participants With Brain Metastasis at Baseline (Cohort 2)
Central nervous system progression free survival rate is the percentage of participants free from central nervous system progression at 12 months, estimated by the Kaplan-Meier method.
Time frame: At 12 Months
Time to New CNS Lesions in Participants With Brain Metastasis at Baseline (Cohort 2)
The time to new CNS lesions is defined as the time from the date of the first dose of study intervention to the date of documented new CNS lesions by RECIST 1.1 per ICR.
Time frame: From first dose (Day 1) to the date of documented new CNS lesions (up to 2 years 7 months)
Central Nervous System Objective Response Rate in Participants With Brain Metastasis at Baseline by ICR (Cohort 2)
The CNS ORR is defined as the percentage of participants with measurable brain metastasis at baseline who have a confirmed CR or confirmed PR of brain lesions, as determined by ICR per CNS RECIST 1.1.
Time frame: From first dose (Day 1) until CNS progression of disease (up to 2 years 7 months)
Central Nervous System Duration of Response in Participants With Brain Metastasis at Baseline (Cohort 2)
The CNS DoR is defined as the time from the date of first documented confirmed CNS response until date of documented CNS progression per CNS RECIST 1.1 as assessed by ICR or death due to any cause.
Time frame: From date of first documented confirmed CNS response until CNS progression of disease (up to 2 years 7 months)
Number of Participants With Best on Treatment Visit Response on the European Organization for the Research and Treatment of Cancer 30-Item Core Quality of Life Questionnaire (EORTC QLQ-C30)
The EORTC QLQ-C30 is a 30-item questionnaire for cancer assessment. Increased scores indicate improvement; decreased scores indicate deterioration. Physical function: ≥+9= improvement, ≤-10=deterioration, otherwise=no change; Role functioning: ≤-6=deterioration, otherwise=no change; Social functioning: ≥+8=improvement, ≤-7=deterioration, otherwise=no change; Cognitive functioning: ≥+ 5=improvement, ≤- 4=deterioration, otherwise=no change; Global Health Status: ≥+2=improvement, ≤-8=deterioration, otherwise=no change; Fatigue: ≥+8=improvement, ≤-8=deterioration, otherwise=no change; Nausea and vomiting: ≤-11=deterioration, otherwise=no change; Appetite loss: ≤-14=deterioration, otherwise=no change; rest of scales: ≥+10=improvement, ≤-10=deterioration, otherwise=no change. Best on treatment response is best response category (improvement, no change, and deterioration) achieved by participants between first dose and 47 days after last dose, and prior to starting any anticancer therapy.
Time frame: Time from first dose up to 47 days after last dose, or prior to starting any subsequent therapy, or for up to 2 years 7 months, whichever occurred first
Number of Participants With Neurologic Assessment in Neuro-Oncology Scale (NANO Scale)
The NANO scale is a clinician-reported assessment of neurologic functioning in neuro-oncology participants. The instrument captures 9 domains (gait, strength, ataxia, sensation, visual fields, facial strength, language, level of consciousness, and behavior) and was developed to provide a simple, objective assessment of neurologic function that would be combined with radiographic assessment to provide an overall outcome assessment for neuro-oncology participants in clinical trials and in daily practice. The soring scale for Gait consists of score range 0-3, Strength consists of score range 0-2, ataxia (upper extremity) consists of scale range 0-2 and sensation as 0. Higher scores indicate worse neurologic function. The response categories reported are changes from first post-baseline score to worst on-treatment score at any point of treatment.
Time frame: Time from first dose up to 47 days after last dose, or prior to starting any subsequent therapy, or for up to 2 years 7 months, whichever occurred first
Cognitive Functions Tests: Paired Associates Learning (PAL) First Attempt Memory Score (PALFAMS)
The PAL is a computerized, self-completed cognitive test used to capture cognitive function, including attention, memory, and executive function. This gamified test included PAL and was a low-burden, highly sensitive, precise measure of cognitive function. The PALFAMS is the number of times a participant chose the correct box on their first attempt when recalling the pattern locations, calculated across all assessed trials. A higher number of events of selecting correct boxes indicates better cognitive function. Here, baseline was the last non-missing value prior to administration of the first dose of study intervention.
Time frame: Baseline, Cycle 5 Day 1, Cycle 9 Day 1, Cycle 13 Day 1, and Cycle 17 Day 1 (21 days cycle)
Cognitive Functions Tests: Paired Associates Learning Total Errors Adjusted (PALTEA)
The PAL is a computerized, self-completed cognitive test used to capture cognitive function, including attention, memory, and executive function. This gamified test included PALTEA and was a low-burden, highly sensitive, precise measure of cognitive function. PALTEA is the number of times a participant chose the incorrect box for a stimulus on assessment problems, plus an adjustment for the estimated number of errors they would have made on any problems, attempts, and recalls they did not reach. A higher number of events of selecting incorrect boxes indicates worse cognitive function. Here, baseline was the last non-missing value prior to administration of the first dose of study intervention.
Time frame: Baseline, Cycle 5 Day 1, Cycle 9 Day 1, Cycle 13 Day 1, and Cycle 17 Day 1 (21 days cycle)
Cognitive Functions Tests: Reaction Time (RTI)
This is a computerized, self-completed cognitive test used to capture cognitive function, including attention, memory, and executive function. This gamified test included Reaction Time Task (RTI) and was low-burden, highly sensitive, precise measures of cognitive function. RTI Median Five-Choice Movement Time: median time taken for a participant to release response button and select target stimulus after it flashed yellow on screen. Calculated across correct, assessed trials in which stimulus could appear in any one of five locations. RTI Median Five-Choice Reaction Time: median duration it took for a participant to release response button after presentation of target stimulus. Calculated across correct, assessed trials in which stimulus could appear in any one of five locations. Measured in milliseconds. Higher reaction times indicate worse cognitive function. Here, baseline was the last non-missing value prior to administration of the first dose of study intervention.
Time frame: Baseline, Cycle 5 Day 1, Cycle 9 Day 1, Cycle 13 Day 1, and Cycle 17 Day 1 (21 days cycle)
Cognitive Functions Tests: Spatial Working Memory (SWM)
The SWM is a computerized cognitive test. The SWM Between Errors (SWMBE) is number of times a participant incorrectly revisits a box in which a token has previously been found, calculated across all 4, 6, and 8 token trials. SWM Between Errors 4 Boxes (SWMBE4), SWM Between Errors 6 Boxes (SWMBE6), and SWM Between Errors 8 Boxes (SWMBE8) are number of times a participant revisits a box in which a token has previously been found. These are calculated across all trials with 4 tokens only for SWMBE4, 6 tokens only for SWMBE6, and 8 tokens only for SWMBE8. SWM Total Errors is number of times a box is selected that is certain not to contain a token and therefore should not have been visited by participant. A higher number of incorrect revisit events to previously found token boxes indicates worse cognitive function, and a lower number of revisit events indicates better cognitive function. Here, baseline was last non-missing value prior to administration of first dose of study intervention.
Time frame: Baseline, Cycle 5 Day 1, Cycle 9 Day 1, Cycle 13 Day 1, and Cycle 17 Day 1 (21 days cycle)
Cognitive Functions Tests: Spatial Working Memory Strategy (SWMS)
The SWM is a computerized cognitive test. The SWMS, the number of times a participant restarted search patterns from the same initial box, indicating their use of a planned strategy to find tokens. An increased number of events where search patterns started from the same initial box suggested participants were using a planned strategy to find tokens, which indicated better cognitive function. Here, a low score indicated high strategy use (1 = they always began the search from the same box). Conversely, high scores represented a decrease in events of beginning searches from the same box. Instead, starting from many different boxes suggested the participant was not using a consistent strategy, which indicated worse cognitive function. This was calculated across assessed trials with 6 tokens or more. Here, baseline was the last non-missing value prior to administration of the first dose of study intervention.
Time frame: Baseline, Cycle 5 Day 1, Cycle 9 Day 1, Cycle 13 Day 1, and Cycle 17 Day 1 (21 days cycle)
St. George's Respiratory Questionnaire - Idiopathic (SGRQ-I) Pulmonary Fibrosis Version in Participants With Interstitial Lung Disease (ILD)/Pneumonitis
The effect of T-DXd on symptoms, functioning, and HRQoL in HER2+ MBC participants with or without baseline brain metastasis was evaluated. The SGRQ-I is an idiopathic pulmonary fibrosis-specific version of the instrument developed and validated for use among participants with idiopathic pulmonary fibrosis, a type of ILD. The SGRQ-I was used to assess the HRQoL among participants who have been diagnosed with ILD/pneumonitis. It includes 34 of the original SGRQ items determined to be most reliable for assessing the HRQoL of participants with idiopathic pulmonary fibrosis. The instrument yields 3 domain scores (symptoms, activity, and impact) as well as a total score, with scores ranging from 0 to 100. Higher scores indicate greater impairment in HRQoL.
Time frame: From time of ILD/pneumonitis diagnosis (every week) until end of safety follow-up (47 days post last dose) (up to 2 years 7 months)
MD Anderson Symptom Inventory Brain Tumor-Specific Items in Brain Metastasis at Baseline Participants
The T-DXd on symptoms, functioning, and HRQoL in HER2+ MBC participants with or without baseline brain metastasis was evaluated. The MDASI brain tumor module includes 9 symptoms specific to brain tumors (weakness on one side of the body, difficulty understanding, difficulty speaking, seizures, difficulty concentrating, problems with vision, change in appearance, change in bowel pattern (diarrhea or constipation), and irritability). These 9 items will be used to capture symptoms associated with brain metastasis for those diagnosed with brain metastasis. Each item is rated on an 11-point numeric rating scale on a scale of 0-10, with higher scores indicating greater symptom severity. Here, baseline was the last non-missing value prior to administration of the first dose of study intervention.
Time frame: Baseline, Cycle 2 Day 1, Cycle 3 Day 1, Cycle 4 Day 1, Cycle 5 Day 1, and Cycle 39 Day 1 (21 days cycle)
Number of Participants With Adverse Events (AEs)
The safety and tolerability of the participants who received T-DXd was evaluated. SAE=Serious adverse events; CTCAE=Common Terminology for Adverse Events
Time frame: From first dose until end of safety follow-up (47 days post last dose) (up to 2 years 7 months)
Number of Participants With Investigator-assessed ILD/Pneumonitis
The number of participants with ILD/Pneumonitis were by grouped term based on Investigator-reported preferred terms. No adjudication was performed.
Time frame: From first dose until end of safety follow-up (47 days post last dose) (up to 2 years 7 months)
Number of Participants With ILD Clinical Symptoms Resolution Among ILD/Pneumonitis Participants Who Have Been Treated With High Dose Steroid
The number of participants with ILD clinical symptoms resolution in ILD/Pneumonitis participants who have been treated with high dose steroid (\>2 mg dexamethasone) were evaluated.
Time frame: From first dose until end of safety follow-up (47 days post last dose) (up to 2 years 7 months)
Participants were enrolled in this study from 22 June 2021 (First participant in) and the analyses presented in this results form are based on a final data cut-off of 08 February 2024 and final database lock of 22 April 2024.
| Milestone | Cohort 1: Trastuzumab Deruxtecan (T-DXd) | Cohort 2: Trastuzumab Deruxtecan (T-DXd) |
|---|---|---|
| Started | 241 | 263 |
| Completed | 30 | 34 |
| Not completed | 211 | 229 |
| Withdrew: Participant ongoing study at data cutoff date of 08feb24 | 167 | 189 |
| Withdrew: By complete response from the participant | 1 | 0 |
| Withdrew: Lost to follow-up | 3 | 3 |
| Withdrew: Death | 13 | 13 |
| Withdrew: Participant reports worsening of the general critical condition and will not continue | 0 | 1 |
| Withdrew: Participant is in poor health and will not come to the study site | 0 | 1 |
| Withdrew: Progression confirmed in magnetic resonance imaging | 0 | 1 |
| Withdrew: Adverse event | 0 | 3 |
| Withdrew: Participant decision | 1 | 0 |
| Withdrew: Sub investigator decision approved by medical monitor | 1 | 0 |
| Withdrew: Participant immediately started next line of treatment | 1 | 0 |
| Withdrew: Participant's decision because the treatment makes them anxious | 1 | 0 |
| Withdrew: Lack of clinical benefit | 1 | 0 |
| Withdrew: Disease progression | 5 | 5 |
| Withdrew: Withdrawal by subject | 14 | 13 |
| Withdrew: Protocol violation | 1 | 0 |
| Withdrew: Physician decision | 2 | 0 |
The ORR is defined as the percentage (%) of participants who have a confirmed complete response (CR) or confirmed partial response (PR), as determined by independent central review (ICR) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.
| Percentage of participants | Cohort 1: Trastuzumab Deruxtecan (T-DXd) |
|---|---|
| Objective Response Rate (ORR) in Cohort 1 (Participants Without Brain Metastasis at Baseline) | 62.7 (56.5 to 68.8) |
The PFS rate is the percentage of participants alive and free of disease progression at 12 months, estimated by the Kaplan-Meier method.
| Percentage of participants | Cohort 2: Trastuzumab Deruxtecan (T-DXd) |
|---|---|
| Progression-free Survival (PFS) Rate at 12 Months in Cohort 2 (Participants With Brain Metastasis at Baseline) | 61.6 (54.92 to 67.61) |
Survival rate is the percentage of participants alive at 12 months, estimated by the Kaplan-Meier method.
| Percentage of Participants | Cohort 1: Trastuzumab Deruxtecan (T-DXd) | Cohort 2: Trastuzumab Deruxtecan (T-DXd) |
|---|---|---|
| Survival Rate at 12 Months | 90.6 (85.97 to 93.80) | 90.3 (85.89 to 93.41) |
The ORR is defined as the percentage of participants who have a confirmed CR or confirmed PR, as determined by ICR per RECIST 1.1.
| Percentage of participants | Cohort 2: Trastuzumab Deruxtecan (T-DXd) |
|---|---|
| Objective Response Rate in Cohort 2 (Participants With Brain Metastasis at Baseline) | 51.7 (45.7 to 57.8) |
Duration of response is defined as the time from the date of first documented confirmed response until date of documented progression per RECIST 1.1 as assessed by ICR or death due to any cause.
| Months | Cohort 1: Trastuzumab Deruxtecan (T-DXd) | Cohort 2: Trastuzumab Deruxtecan (T-DXd) |
|---|---|---|
| Duration of Response (DoR) | NA (9.5 to NA) | NA (8.1 to NA) |
Time to progression by RECIST 1.1 per ICR is defined as the time from the date of the first dose of study intervention to the date of documented disease progression.
| Months | Cohort 1: Trastuzumab Deruxtecan (T-DXd) | Cohort 2: Trastuzumab Deruxtecan (T-DXd) |
|---|---|---|
| Time to Progression | NA (NA to NA) | NA (NA to NA) |
Duration of treatment on subsequent therapy is defined as the time from the date of first dose of a subsequent therapy until date of the last dose of that therapy.
| Months | Cohort 1: Trastuzumab Deruxtecan (T-DXd) | Cohort 2: Trastuzumab Deruxtecan (T-DXd) |
|---|---|---|
| First subsequent line of therapy | 4.4 (3.3 to 6.3) | 6.5 (3.9 to 8.8) |
| First completed subsequent line of therapy | 3.0 (2.1 to 3.5) | 3.0 (2.1 to 3.5) |
Second progression-free survival rate is the percentage of participants alive and free from a second progression on next-line treatment at 12 months, estimated by the Kaplan-Meier method. The second progression is defined as the earliest progression event subsequent to the first anti-cancer therapy after the initial progression.
| Percentage of Participants | Cohort 1: Trastuzumab Deruxtecan (T-DXd) | Cohort 2: Trastuzumab Deruxtecan (T-DXd) |
|---|---|---|
| Second Progression-Free Survival Rate at 12 Months | 81.1 (74.85 to 85.92) | 83.1 (77.46 to 87.44) |
The incidence rate is defined as proportion of participants with new symptomatic CNS metastases during treatment period in participants without symptomatic CNS metastasis at baseline.
| Proportion of participants | Cohort 1: Trastuzumab Deruxtecan (T-DXd) |
|---|---|
| Incidence of New Symptomatic Central Nervous System (CNS) Metastasis During Treatment Without CNS Metastasis at Baseline (Cohort 1) | 0.017 (0.00452 to 0.04250) |
The time to next progression is defined as the time from the date of the first documented isolated CNS progression to the date of the next documented disease progression (CNS or extracranial) per RECIST 1.1 or death and has been summarized descriptively in participants who have developed isolated CNS progression, receive local therapy, and continue on protocol therapy.
| Months | Cohort 1: Trastuzumab Deruxtecan (T-DXd) | Cohort 2: Trastuzumab Deruxtecan (T-DXd) |
|---|---|---|
| Time to Next Progression (CNS or Extracranial) or Death | 3.7 (3.7 to NA) | 0.2 (0.1 to 0.3) |
Site of next progression (CNS \[CNS RECIST 1.1\] or extracranial \[systemic RECIST 1.1\] in participants who developed isolated CNS progression, received local therapy, and continued on protocol therapy.
| Participants | Cohort 1: Trastuzumab Deruxtecan (T-DXd) | Cohort 2: Trastuzumab Deruxtecan (T-DXd) |
|---|---|---|
| CNS | 0 | 6 |
| Extracranial | 0 | 2 |
| Both | 0 | 4 |
Central nervous system progression free survival rate is the percentage of participants free from central nervous system progression at 12 months, estimated by the Kaplan-Meier method.
| Percentage of Participants | Cohort 2: Trastuzumab Deruxtecan (T-DXd) |
|---|---|
| Central Nervous System Progression-free Survival Rate at 12 Months in Participants With Brain Metastasis at Baseline (Cohort 2) | 58.9 (51.93 to 65.30) |
The time to new CNS lesions is defined as the time from the date of the first dose of study intervention to the date of documented new CNS lesions by RECIST 1.1 per ICR.
| Months | Cohort 2: Trastuzumab Deruxtecan (T-DXd) |
|---|---|
| Time to New CNS Lesions in Participants With Brain Metastasis at Baseline (Cohort 2) | NA (NA to NA) |
The CNS ORR is defined as the percentage of participants with measurable brain metastasis at baseline who have a confirmed CR or confirmed PR of brain lesions, as determined by ICR per CNS RECIST 1.1.
| Percentage of participants | Cohort 2: Trastuzumab Deruxtecan (T-DXd) |
|---|---|
| Central Nervous System Objective Response Rate in Participants With Brain Metastasis at Baseline by ICR (Cohort 2) | 71.7 (64.2 to 79.3) |
The CNS DoR is defined as the time from the date of first documented confirmed CNS response until date of documented CNS progression per CNS RECIST 1.1 as assessed by ICR or death due to any cause.
| Months | Cohort 2: Trastuzumab Deruxtecan (T-DXd) |
|---|---|
| Central Nervous System Duration of Response in Participants With Brain Metastasis at Baseline (Cohort 2) | NA (6.9 to NA) |
The EORTC QLQ-C30 is a 30-item questionnaire for cancer assessment. Increased scores indicate improvement; decreased scores indicate deterioration. Physical function: ≥+9= improvement, ≤-10=deterioration, otherwise=no change; Role functioning: ≤-6=deterioration, otherwise=no change; Social functioning: ≥+8=improvement, ≤-7=deterioration, otherwise=no change; Cognitive functioning: ≥+ 5=improvement, ≤- 4=deterioration, otherwise=no change; Global Health Status: ≥+2=improvement, ≤-8=deterioration, otherwise=no change; Fatigue: ≥+8=improvement, ≤-8=deterioration, otherwise=no change; Nausea and vomiting: ≤-11=deterioration, otherwise=no change; Appetite loss: ≤-14=deterioration, otherwise=no change; rest of scales: ≥+10=improvement, ≤-10=deterioration, otherwise=no change. Best on treatment response is best response category (improvement, no change, and deterioration) achieved by participants between first dose and 47 days after last dose, and prior to starting any anticancer therapy.
| Participants | Cohort 1: Trastuzumab Deruxtecan (T-DXd) | Cohort 2: Trastuzumab Deruxtecan (T-DXd) |
|---|---|---|
| Appetite loss: Best on-treatment response: Deterioration | 15 | 9 |
| Appetite loss: Best on-treatment response: No change | 171 | 200 |
| Appetite loss: Best on-treatment response: No follow-up | 21 | 15 |
| Appetite loss: Best on-treatment response: Missing | 0 | 0 |
| Cognitive Functioning: Best on-treatment response: Deterioration | 16 | 12 |
| Cognitive Functioning: Best on-treatment response: Improvement | 57 | 87 |
| Cognitive Functioning: Best on-treatment response: No change | 116 | 107 |
| Cognitive Functioning: Best on-treatment response: No follow-up | 18 | 17 |
| Cognitive Functioning: Best on-treatment response: Missing | 0 | 0 |
| Constipation: Best on-treatment response: Deterioration | 18 | 13 |
| Constipation: Best on-treatment response: Improvement | 36 | 59 |
| Constipation: Best on-treatment response: No change | 134 | 139 |
| Constipation: Best on-treatment response: No follow-up | 19 | 13 |
| Constipation: Best on-treatment response: Missing | 0 | 0 |
| Diarrhoea: Best on-treatment response: Deterioration | 2 | 4 |
| Diarrhoea: Best on-treatment response: Improvement | 32 | 28 |
| Diarrhoea: Best on-treatment response: No change | 153 | 174 |
| Diarrhoea: Best on-treatment response: No follow-up | 20 | 17 |
| Diarrhoea: Best on-treatment response: Missing | 0 | 0 |
| Dyspnea: Best on-treatment response: Deterioration | 6 | 5 |
| Dyspnea: Best on-treatment response: Improvement | 48 | 49 |
| Dyspnea: Best on-treatment response: No change | 131 | 154 |
| Dyspnea: Cycle Best on-treatment response: No follow-up | 22 | 16 |
| Dyspnea: Best on-treatment response: Missing | 0 | 0 |
| Emotional Functioning: Best on-treatment response: Deterioration | 4 | 7 |
| Emotional Functioning: Best on-treatment response: Improvement | 109 | 98 |
| Emotional Functioning: Best on-treatment response: No change | 77 | 103 |
| Emotional Functioning: Best on-treatment response: No follow-up | 17 | 15 |
| Emotional Functioning: Best on-treatment response: Missing | 0 | 0 |
| Fatigue: Best on-treatment response: Deterioration | 28 | 23 |
| Fatigue: Best on-treatment response: Improvement | 97 | 119 |
| Fatigue: Best on-treatment response: No change | 65 | 68 |
| Fatigue: Best on-treatment response: No follow-up | 17 | 14 |
| Fatigue: Best on-treatment response: Missing | 0 | 0 |
| Financial difficulties: Best on-treatment response: Deterioration | 7 | 9 |
| Financial difficulties: Best on-treatment response: Improvement | 46 | 58 |
| Financial difficulties: Best on-treatment response: No change | 135 | 140 |
| Financial difficulties: Best on-treatment response: No follow-up | 18 | 16 |
| Financial difficulties: Best on-treatment response: Missing | 0 | 0 |
| Global health status / QoL: Best on-treatment response: Deterioration | 28 | 34 |
| Global health status / QoL: Best on-treatment response: Improvement | 86 | 111 |
| Global health status / QoL: Best on-treatment response: No change | 75 | 65 |
| Global health status / QoL: Best on-treatment response: No follow-up | 18 | 13 |
| Global health status / QoL: Best on-treatment response: Missing | 0 | 0 |
| Insomnia: Best on-treatment response: Deterioration | 8 | 7 |
| Insomnia: Best on-treatment response: Improvement | 87 | 103 |
| Insomnia: Best on-treatment response: No change | 92 | 98 |
| Insomnia: Best on-treatment response: No follow-up | 20 | 16 |
| Insomnia: Best on-treatment response: Missing | 0 | 0 |
| Nausea and vomiting: Best on-treatment response: Deterioration | 17 | 9 |
| Nausea and vomiting: Best on-treatment response: No change | 167 | 201 |
| Nausea and vomiting: Best on-treatment response: No follow-up | 23 | 14 |
| Nausea and vomiting: Best on-treatment response: Missing | 0 | 0 |
| Pain: Best on-treatment response: Deterioration | 4 | 8 |
| Pain: Best on-treatment response: Improvement | 91 | 115 |
| Pain: Best on-treatment response: No change | 94 | 89 |
| Pain: Best on-treatment response: No follow-up | 18 | 12 |
| Pain: Best on-treatment response: Missing | 0 | 0 |
| Physical Functioning: Best on-treatment response: Deterioration | 10 | 13 |
| Physical Functioning: Best on-treatment response: Improvement | 54 | 71 |
| Physical Functioning: Best on-treatment response: No change | 122 | 124 |
| Physical Functioning: Best on-treatment response: No follow-up | 21 | 16 |
| Physical Functioning: Best on-treatment response: Missing | 0 | 0 |
| Role Functioning: Best on-treatment response: Deterioration | 20 | 15 |
| Role Functioning: Best on-treatment response: No change | 167 | 197 |
| Role Functioning: Best on-treatment response: No follow-up | 20 | 12 |
| Role Functioning: Best on-treatment response: Missing | 0 | 0 |
| Social Functioning: Best on-treatment response: Deterioration | 19 | 16 |
| Social Functioning: Best on-treatment response: Improvement | 81 | 109 |
| Social Functioning: Best on-treatment response: No change | 87 | 83 |
| Social Functioning: Best on-treatment response: No follow-up | 20 | 15 |
| Social Functioning: Best on-treatment response: Missing | 0 | 0 |
The NANO scale is a clinician-reported assessment of neurologic functioning in neuro-oncology participants. The instrument captures 9 domains (gait, strength, ataxia, sensation, visual fields, facial strength, language, level of consciousness, and behavior) and was developed to provide a simple, objective assessment of neurologic function that would be combined with radiographic assessment to provide an overall outcome assessment for neuro-oncology participants in clinical trials and in daily practice. The soring scale for Gait consists of score range 0-3, Strength consists of score range 0-2, ataxia (upper extremity) consists of scale range 0-2 and sensation as 0. Higher scores indicate worse neurologic function. The response categories reported are changes from first post-baseline score to worst on-treatment score at any point of treatment.
| Participants | Cohort 1: Trastuzumab Deruxtecan (T-DXd) | Cohort 2: Trastuzumab Deruxtecan (T-DXd) |
|---|---|---|
| Neurologic response | 3 | 4 |
| Neurologic stability | 217 | 220 |
| Neurologic progression | 16 | 25 |
| Not assessed | 0 | 5 |
| Non-evaluable | 0 | 0 |
The PAL is a computerized, self-completed cognitive test used to capture cognitive function, including attention, memory, and executive function. This gamified test included PAL and was a low-burden, highly sensitive, precise measure of cognitive function. The PALFAMS is the number of times a participant chose the correct box on their first attempt when recalling the pattern locations, calculated across all assessed trials. A higher number of events of selecting correct boxes indicates better cognitive function. Here, baseline was the last non-missing value prior to administration of the first dose of study intervention.
| Number of Events | Cohort 1: Trastuzumab Deruxtecan (T-DXd) | Cohort 2: Trastuzumab Deruxtecan (T-DXd) |
|---|---|---|
| Paired Assistance Learning (PAL) first attempt Memory score: Baseline | 10.9 ± 4.63 | 10.4 ± 4.71 |
| PAL first attempt Memory score: Cycle 5 Day 1 | 11.7 ± 4.81 | 10.8 ± 4.48 |
| PAL first attempt Memory score: Cycle 9 Day 1 | 12.5 ± 4.36 | 11.4 ± 4.59 |
| PAL first attempt Memory score: Cycle 13 Day 1 | 12.4 ± 4.86 | 11.8 ± 4.56 |
| PAL first attempt Memory score: Cycle 17 Day 1 | 13.2 ± 4.61 | 12.2 ± 5.07 |
The PAL is a computerized, self-completed cognitive test used to capture cognitive function, including attention, memory, and executive function. This gamified test included PALTEA and was a low-burden, highly sensitive, precise measure of cognitive function. PALTEA is the number of times a participant chose the incorrect box for a stimulus on assessment problems, plus an adjustment for the estimated number of errors they would have made on any problems, attempts, and recalls they did not reach. A higher number of events of selecting incorrect boxes indicates worse cognitive function. Here, baseline was the last non-missing value prior to administration of the first dose of study intervention.
| Number of Events | Cohort 1: Trastuzumab Deruxtecan (T-DXd) | Cohort 2: Trastuzumab Deruxtecan (T-DXd) |
|---|---|---|
| PAL Total Errors (Adjusted): Baseline | 21.8 ± 17.18 | 24.8 ± 17.59 |
| PAL Total Errors (Adjusted): Cycle 5 Day 1 | 19.2 ± 16.47 | 23.1 ± 17.53 |
| PAL Total Errors (Adjusted): Cycle 9 Day 1 | 17.2 ± 15.17 | 21.5 ± 17.32 |
| PAL Total Errors (Adjusted): Cycle 13 Day 1 | 17.5 ± 16.33 | 19.2 ± 16.31 |
| PAL Total Errors (Adjusted): Cycle 17 Day 1 | 15.0 ± 14.92 | 19.2 ± 17.66 |
This is a computerized, self-completed cognitive test used to capture cognitive function, including attention, memory, and executive function. This gamified test included Reaction Time Task (RTI) and was low-burden, highly sensitive, precise measures of cognitive function. RTI Median Five-Choice Movement Time: median time taken for a participant to release response button and select target stimulus after it flashed yellow on screen. Calculated across correct, assessed trials in which stimulus could appear in any one of five locations. RTI Median Five-Choice Reaction Time: median duration it took for a participant to release response button after presentation of target stimulus. Calculated across correct, assessed trials in which stimulus could appear in any one of five locations. Measured in milliseconds. Higher reaction times indicate worse cognitive function. Here, baseline was the last non-missing value prior to administration of the first dose of study intervention.
| Millisecond (msec) | Cohort 1: Trastuzumab Deruxtecan (T-DXd) | Cohort 2: Trastuzumab Deruxtecan (T-DXd) |
|---|---|---|
| Reaction time (RTI) Median Five-Choice Movement Time: Baseline | 314.7 ± 117.03 | 329.4 ± 141.24 |
| RTI Median Five-Choice Movement Time: Cycle 5 Day 1 | 309.1 ± 94.85 | 310.5 ± 110.94 |
| RTI Median Five-Choice Movement Time: Cycle 9 Day 1 | 305.3 ± 93.47 | 326.7 ± 106.02 |
| RTI Median Five-Choice Movement Time: Cycle 13 Day 1 | 308.4 ± 89.55 | 324.1 ± 115.24 |
| RTI Median Five-Choice Movement Time: Cycle 17 Day 1 | 319.6 ± 151.42 | 316.4 ± 96.69 |
| RTI Median Five-Choice Reaction Time: Baseline | 401.3 ± 70.63 | 423.6 ± 115.56 |
| RTI Median Five-Choice Reaction Time: Cycle 5 Day 1 | 408.7 ± 119.26 | 413.0 ± 84.25 |
| RTI Median Five-Choice Reaction Time: Cycle 9 Day 1 | 401.5 ± 73.18 | 414.5 ± 67.68 |
| RTI Median Five-Choice Reaction Time: Cycle 13 Day 1 | 401.0 ± 63.56 | 412.3 ± 77.07 |
| RTI Median Five-Choice Reaction Time: Cycle 17 Day 1 | 396.8 ± 81.63 | 402.8 ± 51.93 |
The SWM is a computerized cognitive test. The SWM Between Errors (SWMBE) is number of times a participant incorrectly revisits a box in which a token has previously been found, calculated across all 4, 6, and 8 token trials. SWM Between Errors 4 Boxes (SWMBE4), SWM Between Errors 6 Boxes (SWMBE6), and SWM Between Errors 8 Boxes (SWMBE8) are number of times a participant revisits a box in which a token has previously been found. These are calculated across all trials with 4 tokens only for SWMBE4, 6 tokens only for SWMBE6, and 8 tokens only for SWMBE8. SWM Total Errors is number of times a box is selected that is certain not to contain a token and therefore should not have been visited by participant. A higher number of incorrect revisit events to previously found token boxes indicates worse cognitive function, and a lower number of revisit events indicates better cognitive function. Here, baseline was last non-missing value prior to administration of first dose of study intervention.
| Number of Events | Cohort 1: Trastuzumab Deruxtecan (T-DXd) | Cohort 2: Trastuzumab Deruxtecan (T-DXd) |
|---|---|---|
| Spatial working memory (SWM) Between Errors: Baseline | 17.2 ± 8.89 | 18.6 ± 8.69 |
| SWM Between Errors: Cycle 5 Day 1 | 15.5 ± 10.11 | 16.8 ± 8.39 |
| SWM Between Errors: Cycle 9 Day 1 | 15.1 ± 9.78 | 16.3 ± 9.22 |
| SWM Between Errors: Cycle 13 Day 1 | 13.4 ± 9.56 | 15.0 ± 8.85 |
| SWM Between Errors: Cycle 17 Day 1 | 13.5 ± 9.48 | 13.7 ± 9.50 |
| SWM Between Errors 4 Boxes: Baseline | 1.4 ± 1.39 | 1.4 ± 1.46 |
| SWM Between Errors 4 Boxes: Cycle 5 Day 1 | 1.0 ± 1.39 | 1.1 ± 1.42 |
| SWM Between Errors 4 Boxes: Cycle 9 Day 1 | 0.9 ± 1.33 | 1.1 ± 1.42 |
| SWM Between Errors 4 Boxes: Cycle 13 Day 1 | 0.8 ± 1.23 | 0.9 ± 1.37 |
| SWM Between Errors 4 Boxes: Cycle 17 Day 1 | 0.9 ± 1.32 | 0.7 ± 1.17 |
| SWM Between Errors 6 Boxes: Baseline | 5.0 ± 3.44 | 5.2 ± 3.53 |
| SWM Between Errors 6 Boxes: Cycle 5 Day 1 | 4.3 ± 3.41 | 4.6 ± 3.42 |
| SWM Between Errors 6 Boxes: Cycle 9 Day 1 | 4.2 ± 3.64 | 4.7 ± 3.84 |
| SWM Between Errors 6 Boxes: Cycle 13 Day 1 | 3.2 ± 3.38 | 4.1 ± 3.34 |
| SWM Between Errors 6 Boxes: Cycle 17 Day 1 | 3.7 ± 3.25 | 4.0 ± 3.51 |
| SWM Between Errors 8 Boxes: Baseline | 10.9 ± 5.66 | 12.1 ± 5.45 |
| SWM Between Errors 8 Boxes: Cycle 5 Day 1 | 10.2 ± 6.61 | 11.2 ± 5.31 |
| SWM Between Errors 8 Boxes: Cycle 9 Day 1 | 10.0 ± 6.31 | 10.5 ± 5.52 |
| SWM Between Errors 8 Boxes: Cycle 13 Day 1 | 9.3 ± 6.27 | 9.9 ± 5.91 |
| SWM Between Errors 8 Boxes: Cycle 17 Day 1 | 8.9 ± 6.42 | 9.0 ± 6.33 |
| SWM Total Errors: Baseline | 17.5 ± 8.96 | 19.0 ± 8.75 |
| SWM Total Errors: Cycle 5 Day 1 | 15.9 ± 10.24 | 17.3 ± 8.59 |
| SWM Total Errors: Cycle 9 Day 1 | 15.5 ± 9.89 | 16.7 ± 9.42 |
| SWM Total Errors: Cycle 13 Day 1 | 13.7 ± 9.71 | 15.3 ± 8.91 |
| SWM Total Errors: Cycle 17 Day 1 | 13.8 ± 9.63 | 13.9 ± 9.63 |
The SWM is a computerized cognitive test. The SWMS, the number of times a participant restarted search patterns from the same initial box, indicating their use of a planned strategy to find tokens. An increased number of events where search patterns started from the same initial box suggested participants were using a planned strategy to find tokens, which indicated better cognitive function. Here, a low score indicated high strategy use (1 = they always began the search from the same box). Conversely, high scores represented a decrease in events of beginning searches from the same box. Instead, starting from many different boxes suggested the participant was not using a consistent strategy, which indicated worse cognitive function. This was calculated across assessed trials with 6 tokens or more. Here, baseline was the last non-missing value prior to administration of the first dose of study intervention.
| Number of Events | Cohort 1: Trastuzumab Deruxtecan (T-DXd) | Cohort 2: Trastuzumab Deruxtecan (T-DXd) |
|---|---|---|
| SWM Strategy (6-8 Boxes): Baseline | 8.8 ± 2.30 | 9.1 ± 2.32 |
| SWM Strategy (6-8 Boxes): Cycle 5 Day 1 | 8.4 ± 2.80 | 8.8 ± 2.42 |
| SWM Strategy (6-8 Boxes): Cycle 9 Day 1 | 8.2 ± 2.70 | 8.5 ± 2.44 |
| SWM Strategy (6-8 Boxes): Cycle 13 Day 1 | 7.9 ± 3.18 | 8.6 ± 2.79 |
| SWM Strategy (6-8 Boxes): Cycle 17 Day 1 | 7.9 ± 3.13 | 8.0 ± 3.08 |
The effect of T-DXd on symptoms, functioning, and HRQoL in HER2+ MBC participants with or without baseline brain metastasis was evaluated. The SGRQ-I is an idiopathic pulmonary fibrosis-specific version of the instrument developed and validated for use among participants with idiopathic pulmonary fibrosis, a type of ILD. The SGRQ-I was used to assess the HRQoL among participants who have been diagnosed with ILD/pneumonitis. It includes 34 of the original SGRQ items determined to be most reliable for assessing the HRQoL of participants with idiopathic pulmonary fibrosis. The instrument yields 3 domain scores (symptoms, activity, and impact) as well as a total score, with scores ranging from 0 to 100. Higher scores indicate greater impairment in HRQoL.
| Score on scale | Cohort 1: Trastuzumab Deruxtecan (T-DXd) | Cohort 2: Trastuzumab Deruxtecan (T-DXd) |
|---|---|---|
| Total: Baseline | 32.1 ± 19.31 | 27.6 ± 20.97 |
| Total: Week 1 | 28.2 ± 17.10 | 33.1 ± 30.33 |
| Total: Week 2 | 23.3 ± 22.91 | 21.5 ± 14.48 |
| Total: Week 3 | 19.5 ± 20.10 | 15.3 ± 15.23 |
| Total: Week 4 | 4.2 ± 1.09 | 17.8 ± 15.49 |
| Total: Week 5 | 8.0 ± 6.40 | 15.9 ± 15.43 |
| Total: Week 6 | 6.7 ± 2.39 | 16.4 ± 11.95 |
| Total: Week 7 | 5.4 ± 3.49 | 14.8 ± 15.73 |
| Total: Week 8 | 3.3 ± 1.75 | 16.9 ± 17.04 |
| Total: Week 9 | 8.0 ± 4.29 | 23.3 ± 17.20 |
| Total: Week 10 | 6.6 ± 2.36 | 18.6 ± 14.54 |
| Total: Week 11 | 8.9 ± 1.79 | 20.3 ± 14.92 |
| Total: Week 12 | 8.4 ± 2.73 | 21.8 ± 14.40 |
| Total: Week 13 | 6.2 ± 0.27 | 20.4 ± 17.95 |
| Total: Week 14 | 5.5 ± 2.97 | 8.6 ± 7.19 |
| Total: Week 15 | 4.2 ± 1.09 | 12.9 ± 10.49 |
| Total: Week 16 | 4.2 ± 1.09 | 12.3 ± 10.10 |
| Total: Week 17 | 4.2 ± 1.09 | 12.1 ± 15.07 |
| Total: Week 18 | 4.2 ± 1.09 | 13.3 ± 16.29 |
| Total: Week 19 | 9.1 ± 7.02 | 8.7 ± 9.07 |
| Total: Week 20 | 7.9 ± 6.41 | 6.2 ± 3.86 |
| Total: Week 21 | 7.5 ± 5.78 | 5.2 ± 2.58 |
| Total: Week 22 | 6.7 ± 2.44 | 15.4 ± 13.24 |
| Total: Week 23 | 6.7 ± 2.44 | 9.8 ± 9.74 |
| Total: Week 24 | 6.7 ± 2.44 | 17.3 ± 15.09 |
| Total: Week 25 | 5.6 ± 2.56 | 11.0 ± 10.90 |
| Total: Week 26 | 5.6 ± 2.56 | 10.5 ± 10.81 |
| Total: Week 27 | 5.6 ± 2.56 | 13.5 ± 11.53 |
| Total: Week 28 | 5.6 ± 2.56 | 10.7 ± 11.13 |
| Total: Week 29 | 6.7 ± 2.44 | 16.5 ± 16.52 |
| Total: Week 30 | 4.7 ± 1.19 | 19.6 ± 18.60 |
| Total: Week 31 | 5.6 ± 2.56 | 15.9 ± 13.98 |
| Total: Week 32 | 5.6 ± 2.56 | 11.4 ± 10.89 |
| Total: Week 33 | 6.7 ± 2.44 | 5.2 ± 3.15 |
| Total: Week 34 | 5.5 ± 2.62 | 11.9 ± 10.36 |
| Total: Week 35 | 6.6 ± 2.76 | 11.9 ± 10.32 |
| Total: Week 36 | 6.7 ± 2.44 | 15.9 ± 17.62 |
| Total: Week 37 | 5.4 ± 2.45 | 11.5 ± 9.72 |
| Total: Week 38 | 6.7 ± 2.44 | 11.8 ± 10.13 |
| Total: Week 39 | 5.0 ± NA | 6.2 ± 3.86 |
| Total: Week 40 | 5.6 ± 2.56 | 6.2 ± 3.86 |
| Total: Week 41 | 5.6 ± 2.56 | 8.9 ± NA |
| Total: Week 42 | 6.7 ± 2.44 | 6.2 ± 3.86 |
| Total: Week 43 | 5.6 ± 2.56 | 6.2 ± 3.86 |
| Total: Week 44 | 7.4 ± 5.54 | 6.2 ± 3.86 |
| Total: Week 45 | 9.5 ± NA | 6.2 ± 3.86 |
| Total: Week 46 | 6.7 ± 2.44 | 8.9 ± NA |
| Total: Week 47 | 6.7 ± 2.44 | 6.2 ± 3.86 |
| Total: Week 48 | 6.7 ± 2.44 | 6.2 ± 3.86 |
| Total: Week 49 | 6.7 ± 2.44 | 8.9 ± NA |
| Total: Week 50 | 9.1 ± 0.99 | 6.2 ± 3.86 |
| Total: Week 51 | 8.2 ± 0.32 | 10.4 ± NA |
| Total: Week 52 | 6.7 ± 2.44 | — |
| Total: Week 53 | 6.7 ± 2.44 | 8.9 ± NA |
| Total: Week 54 | 6.7 ± 2.44 | 8.9 ± NA |
| Total: Week 55 | 6.7 ± 2.44 | 8.9 ± NA |
| Total: Week 56 | 7.5 ± 3.53 | 8.9 ± NA |
| Total: Week 57 | 8.4 ± NA | 8.9 ± NA |
| Total: Week 58 | 8.4 ± NA | 8.9 ± NA |
| Total: Week 59 | 10.0 ± NA | 8.9 ± NA |
| Total: Week 60 | 8.4 ± NA | 8.9 ± NA |
| Total: Week 61 | 8.4 ± NA | 8.9 ± NA |
| Total: Week 62 | 8.4 ± NA | 8.9 ± NA |
| Total: Week 63 | 10.0 ± NA | 8.9 ± NA |
| Total: Week 64 | 8.4 ± NA | 8.9 ± NA |
| Total: Week 65 | — | 8.9 ± NA |
| Total: Week 66 | — | 8.9 ± NA |
| Total: Week 67 | — | 8.9 ± NA |
| Total: Week 68 | — | 8.9 ± NA |
| Total: Week 69 | — | 8.9 ± NA |
| Total: Week 70 | — | 8.9 ± NA |
| Total: Week 71 | — | 8.9 ± NA |
| Total: Week 72 | — | 8.9 ± NA |
| End of treatment | 31.1 ± 18.65 | 18.0 ± 19.16 |
| Safety Follow-up | 23.4 ± 6.38 | 21.4 ± 25.36 |
The T-DXd on symptoms, functioning, and HRQoL in HER2+ MBC participants with or without baseline brain metastasis was evaluated. The MDASI brain tumor module includes 9 symptoms specific to brain tumors (weakness on one side of the body, difficulty understanding, difficulty speaking, seizures, difficulty concentrating, problems with vision, change in appearance, change in bowel pattern (diarrhea or constipation), and irritability). These 9 items will be used to capture symptoms associated with brain metastasis for those diagnosed with brain metastasis. Each item is rated on an 11-point numeric rating scale on a scale of 0-10, with higher scores indicating greater symptom severity. Here, baseline was the last non-missing value prior to administration of the first dose of study intervention.
| Score on scale | Cohort 2: Trastuzumab Deruxtecan (T-DXd) |
|---|---|
| Change in Appearance at Its Worst: Baseline | 1.8 ± 2.44 |
| Change in Appearance at Its Worst: Cycle 2 Day 1 | 1.9 ± 2.44 |
| Change in Appearance at Its Worst: Cycle 3 Day 1 | 2.1 ± 2.51 |
| Change in Appearance at Its Worst: Cycle 4 Day 1 | 1.9 ± 2.20 |
| Change in Appearance at Its Worst: Cycle 5 Day 1 | 2.1 ± 2.45 |
| Change in Appearance at Its Worst: Cycle 39 Day 1 | 3.0 ± NA |
| Change in Bowel Pattern at Its Worst: Baseline | 1.7 ± 2.46 |
| Change in Bowel Pattern at Its Worst: Cycle 2 Day 1 | 2.5 ± 2.55 |
| Change in Bowel Pattern at Its Worst: Cycle 3 Day 1 | 2.7 ± 2.67 |
| Change in Bowel Pattern at Its Worst: Cycle 4 Day 1 | 3.0 ± 2.74 |
| Change in Bowel Pattern at Its Worst: Cycle 5 Day 1 | 2.8 ± 2.69 |
| Change in Bowel Pattern at Its Worst: Cycle 39 Day 1 | 0 ± NA |
| Difficulty Concentrating at Its Worst: Baseline | 1.8 ± 2.23 |
| Difficulty Concentrating at Its Worst: Cycle 2 Day 1 | 1.7 ± 2.03 |
| Difficulty Concentrating at Its Worst: Cycle 3 Day 1 | 1.9 ± 2.27 |
| Difficulty Concentrating at Its Worst: Cycle 4 Day 1 | 1.6 ± 2.03 |
| Difficulty Concentrating at Its Worst: Cycle 5 Day 1 | 1.5 ± 1.95 |
| Difficulty Concentrating at Its Worst: Cycle 39 Day 1 | 1.0 ± NA |
| Difficulty Speaking at Its Worst: Baseline | 1.4 ± 2.18 |
| Difficulty Speaking at Its Worst: Cycle 2 Day 1 | 1.3 ± 1.96 |
| Difficulty Speaking at Its Worst: Cycle 3 Day 1 | 1.4 ± 1.97 |
| Difficulty Speaking at Its Worst: Cycle 4 Day 1 | 1.1 ± 1.80 |
| Difficulty Speaking at Its Worst: Cycle 5 Day 1 | 1.3 ± 1.98 |
| Difficulty Speaking at Its Worst: Cycle 39 Day 1 | 1.0 ± NA |
| Difficulty Understanding at Its Worst: Baseline | 1.5 ± 2.29 |
| Difficulty Understanding at Its Worst: Cycle 2 Day 1 | 0.9 ± 1.67 |
| Difficulty Understanding at Its Worst: Cycle 3 Day 1 | 1.2 ± 1.87 |
| Difficulty Understanding at Its Worst: Cycle 4 Day 1 | 1.0 ± 1.83 |
| Difficulty Understanding at Its Worst: Cycle 5 Day 1 | 0.9 ± 1.68 |
| Difficulty Understanding at Its Worst: Cycle 39 Day 1 | 0 ± NA |
| Irritability at its Worst: Baseline | 1.8 ± 2.27 |
| Irritability at its Worst: Cycle 2 Day 1 | 1.9 ± 2.23 |
| Irritability at its Worst: Cycle 3 Day 1 | 1.8 ± 2.04 |
| Irritability at its Worst: Cycle 4 Day 1 | 1.9 ± 2.06 |
| Irritability at its Worst: Cycle 5 Day 1 | 1.9 ± 2.12 |
| Irritability at its Worst: Cycle 39 Day 1 | 4.0 ± NA |
| Seizures at Its Worst: Baseline | 0.5 ± 1.58 |
| Seizures at Its Worst: Cycle 2 Day 1 | 0.5 ± 1.38 |
| Seizures at Its Worst: Cycle 3 Day 1 | 0.5 ± 1.52 |
| Seizures at Its Worst: Cycle 4 Day 1 | 0.5 ± 1.47 |
| Seizures at Its Worst: Cycle 5 Day 1 | 0.5 ± 1.40 |
| Seizures at Its Worst: Cycle 39 Day 1 | 0 ± NA |
| Vision at Its Worst: Baseline | 1.6 ± 2.28 |
| Vision at Its Worst: Cycle 2 Day 1 | 1.6 ± 2.24 |
| Vision at Its Worst: Cycle 3 Day 1 | 1.5 ± 2.10 |
| Vision at Its Worst: Cycle 4 Day 1 | 1.4 ± 1.94 |
| Vision at Its Worst: Cycle 5 Day 1 | 1.5 ± 2.01 |
| Vision at Its Worst: Cycle 39 Day 1 | 1.0 ± NA |
| Weakness on One Body Side at Its Worst: Baseline | 2.1 ± 2.54 |
| Weakness on One Body Side at Its Worst: Cycle 2 Day 1 | 1.7 ± 2.35 |
| Weakness on One Body Side at Its Worst: Cycle 3 Day 1 | 1.8 ± 2.28 |
| Weakness on One Body Side at Its Worst: Cycle 4 Day 1 | 1.8 ± 2.48 |
| Weakness on One Body Side at Its Worst: Cycle 5 Day 1 | 1.6 ± 2.18 |
| Weakness on One Body Side at Its Worst: Cycle 39 Day 1 | 0 ± NA |
The safety and tolerability of the participants who received T-DXd was evaluated. SAE=Serious adverse events; CTCAE=Common Terminology for Adverse Events
| Participants | Cohort 1: Trastuzumab Deruxtecan (T-DXd) | Cohort 2: Trastuzumab Deruxtecan (T-DXd) |
|---|---|---|
| Any AE | 237 | 259 |
| Any AE, excluding AEs associated with COVID-19 | 237 | 259 |
| Any AE associated with COVID-19 | 45 | 54 |
| Any AE possibly related to treatment | 230 | 242 |
| Any AE of CTCAE grade 3 or higher | 118 | 134 |
| Any AE of CTCAE grade 3 or higher, possibly related to treatment | 98 | 100 |
| Any AE with outcome = death | 6 | 8 |
| Any AE with outcome = death, excluding AEs associated with COVID-19 | 6 | 8 |
| Any AE with outcome = death, associated with COVID-19 | 0 | 0 |
| Any AE with outcome = death, possibly related to treatment | 5 | 6 |
| Any SAE (events with outcome = death) | 46 | 62 |
| Any SAE (events with outcome = death), possibly related to treatment | 25 | 25 |
| Any AE leading to dose reduction | 65 | 60 |
| Any AE leading to dose reduction, possibly related to treatment | 63 | 53 |
| Any AE leading to dose interruption | 124 | 146 |
| Any AE leading to dose interruption, possibly related to treatment | 82 | 83 |
| Any AE leading to discontinuation of treatment | 23 | 40 |
| Any AE leading to discontinuation of treatment, excluding AEs associated with COVID-19 | 23 | 39 |
| Any AE leading to discontinuation of treatment, associated with COVID-19 | 0 | 1 |
| Any AE leading to discontinuation of treatment, possibly related to treatment | 20 | 34 |
| Any SAE leading to discontinuation of treatment | 8 | 18 |
| Any SAE leading to discontinuation of treatment, possibly related to treatment | 6 | 13 |
| Any Other Adverse events (OAE) | 0 | 5 |
| Any Adverse event of special event | 54 | 71 |
The number of participants with ILD/Pneumonitis were by grouped term based on Investigator-reported preferred terms. No adjudication was performed.
| Participants | Cohort 1: Trastuzumab Deruxtecan (T-DXd) | Cohort 2: Trastuzumab Deruxtecan (T-DXd) |
|---|---|---|
| Interstitial lung disease | 19 | 17 |
| Lung opacity | 2 | 0 |
| Pneumonitis | 10 | 24 |
| Pulmonary fibrosis | 1 | 1 |
| Radiation pneumonitis | 1 | 0 |
| Lung infiltration | 0 | 1 |
The number of participants with ILD clinical symptoms resolution in ILD/Pneumonitis participants who have been treated with high dose steroid (\>2 mg dexamethasone) were evaluated.
| Participants | Cohort 1: Trastuzumab Deruxtecan (T-DXd) | Cohort 2: Trastuzumab Deruxtecan (T-DXd) |
|---|---|---|
| Resolved: Recovered/resolved | 18 | 24 |
| Resolved: Recovering/resolving | 1 | 2 |
| Resolved: Recovered/resolved with sequelae | 1 | 1 |
| Unresolved: Not recovered/resolved | 6 | 6 |
| Unresolved: Fatal | 3 | 6 |
Collected over From first dose until end of safety follow-up (47 days post last dose) (up to 2 years 7 months). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort 1: Trastuzumab Deruxtecan (T-DXd) | 41/241 (17%) | 46/241 (19.1%) | 235/241 (97.5%) |
| Cohort 2: Trastuzumab Deruxtecan (T-DXd) | 43/263 (16.3%) | 62/263 (23.6%) | 253/263 (96.2%) |
| Event | Cohort 1: Trastuzumab Deruxtecan (T-DXd) | Cohort 2: Trastuzumab Deruxtecan (T-DXd) |
|---|---|---|
| PneumoniaInfections and infestations | 7/241 | 3/263 |
| PneumonitisRespiratory, thoracic and mediastinal disorders | 4/241 | 7/263 |
| NauseaGastrointestinal disorders | 3/241 | 6/263 |
| HypokalaemiaMetabolism and nutrition disorders | 5/241 | 0/263 |
| AnaemiaBlood and lymphatic system disorders | 3/241 | 5/263 |
| SeizureNervous system disorders | 0/241 | 5/263 |
| VomitingGastrointestinal disorders | 4/241 | 1/263 |
| EpilepsyNervous system disorders | 1/241 | 4/263 |
| COVID-19Infections and infestations | 3/241 | 0/263 |
| HeadacheNervous system disorders | 0/241 | 3/263 |
| Event | Cohort 1: Trastuzumab Deruxtecan (T-DXd) | Cohort 2: Trastuzumab Deruxtecan (T-DXd) |
|---|---|---|
| NauseaGastrointestinal disorders | 171/241 | 168/263 |
| AstheniaGeneral disorders | 103/241 | 71/263 |
| ConstipationGastrointestinal disorders | 98/241 | 105/263 |
| FatigueGeneral disorders | 77/241 | 95/263 |
| DiarrhoeaGastrointestinal disorders | 85/241 | 74/263 |
| AlopeciaSkin and subcutaneous tissue disorders | 83/241 | 75/263 |
| VomitingGastrointestinal disorders | 80/241 | 73/263 |
| NeutropeniaBlood and lymphatic system disorders | 63/241 | 58/263 |
| AnaemiaBlood and lymphatic system disorders | 62/241 | 67/263 |
| HeadacheNervous system disorders | 48/241 | 55/263 |
| Age, Continuous(Years) | Cohort 1: Trastuzumab Deruxtecan (T-DXd) | Cohort 2: Trastuzumab Deruxtecan (T-DXd) | Total |
|---|---|---|---|
| Mean | 54.8 ± 11.9 | 52.8 ± 11.2 | 53.8 ± 11.6 |
| Sex: Female, Male(Participants) | Cohort 1: Trastuzumab Deruxtecan (T-DXd) | Cohort 2: Trastuzumab Deruxtecan (T-DXd) | Total |
|---|---|---|---|
| Female | 241 | 263 | 504 |
| Male | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Cohort 1: Trastuzumab Deruxtecan (T-DXd) | Cohort 2: Trastuzumab Deruxtecan (T-DXd) | Total |
|---|---|---|---|
| Asian | 15 | 19 | 34 |
| Black or African American | 2 | 4 | 6 |
| White | 209 | 231 | 440 |
| Other | 13 | 6 | 19 |
| Not reported | 1 | 1 | 2 |
| Missing | 1 | 2 | 3 |
| Race/Ethnicity, Customized(Participants) | Cohort 1: Trastuzumab Deruxtecan (T-DXd) | Cohort 2: Trastuzumab Deruxtecan (T-DXd) | Total |
|---|---|---|---|
| Hispanic or Latino | 20 | 15 | 35 |
| Not Hispanic or Latino | 219 | 245 | 464 |
| Missing | 2 | 3 | 5 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
Supporting information: Study protocol, Statistical analysis plan
Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool. Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com
Ran from Jun 2021 to primary completion in Feb 2024, 31 months.
Results were first posted in May 2025, 1 year 3 months after primary completion.
Of 272 industry-sponsored phase 3 interventional studies under Breast Neoplasms, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 63. This study's 31 months is below that.
Counting every sponsor, half of 600 studies reached it within 59 months; a quarter within 36 and three quarters within 96.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Trastuzumab deruxtecan